Enanta Pharma (ENTA) Misses Q2 EPS by 5c
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of ($0.06), $0.05 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $14 million versus the consensus estimate of $13.05 million.
For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mondelez Int'l (MDLZ) Tops Q3 EPS by 9c, Offers Outlook
- Bok Financial Corp (BOKF) Tops Q3 EPS by 3c
- Logitech (LOGI) Tops Q2 EPS by 10c
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!